Page 86 - Read Online
P. 86

Annibali et al. Mini-invasive Surg 2022;6:12  https://dx.doi.org/10.20517/2574-1225.2021.101  Page 15 of 16

               62.      Mack MJ, Leon MB, Thourani VH, et al; PARTNER 3 Investigators. Transcatheter aortic-valve replacement with a balloon-
                   expandable valve in low-risk patients. N Engl J Med 2019;380:1695-705.  DOI  PubMed
               63.      Popma JJ, Deeb GM, Yakubov SJ, et al; Evolut Low Risk Trial Investigators. Transcatheter aortic-valve replacement with a self-
                   expanding valve in low-risk patients. N Engl J Med 2019;380:1706-15.  DOI  PubMed
               64.      Tarantini G, Nai Fovino L. Lifetime strategy of patients with aortic stenosis: the first cut is the deepest. JACC Cardiovasc Interv
                   2021;14:1727-30.  DOI  PubMed
               65.      Tarantini G, Nai Fovino L, Le Prince P, et al. Coronary access and percutaneous coronary intervention up to 3 years after transcatheter
                   aortic valve implantation with a balloon-expandable valve. Circ Cardiovasc Interv 2020;13:e008972.  DOI  PubMed  PMC
               66.      Bapat VN, Zaid S, Fukuhara S, et al; EXPLANT-TAVR Investigators. Surgical explantation after TAVR failure: Mid-term outcomes
                   from the EXPLANT-TAVR international registry. JACC Cardiovasc Interv 2021;14:1978-91.  DOI  PubMed
               67.      Fukuhara S, Brescia AA, Shiomi S, et al. Surgical explantation of transcatheter aortic bioprostheses: results and clinical implications. J
                   Thorac Cardiovasc Surg 2021;162:539-47.e1.  DOI  PubMed  PMC
               68.      Percy ED, Harloff MT, Hirji S, et al. Nationally representative repeat transcatheter aortic valve replacement outcomes: report from the
                   centers for medicare and medicaid services. JACC Cardiovasc Interv 2021;14:1717-26.  DOI  PubMed
               69.      Hirji SA, Percy ED, McGurk S, et al. Incidence, characteristics, predictors, and outcomes of surgical explantation after transcatheter
                   aortic valve replacement. J Am Coll Cardiol 2020;76:1848-59.  DOI  PubMed
               70.      Landes U, Webb JG, De Backer O, et al. Repeat transcatheter aortic valve replacement for transcatheter prosthesis dysfunction. J Am
                   Coll Cardiol 2020;75:1882-93.  DOI  PubMed
               71.      Attizzani GF, Ohno Y, Latib A, et al. Acute and long-term (2-years) clinical outcomes of the CoreValve 31mm in large aortic annuli: a
                   multicenter study. Int J Cardiol 2017;227:543-9.  DOI  PubMed
               72.      Barbanti M, Webb JG, Tamburino C, et al. Outcomes of redo transcatheter aortic valve replacement for the treatment of postprocedural
                   and late occurrence of paravalvular regurgitation and transcatheter valve failure. Circ Cardiovasc Interv 2016;9:e003930.  DOI
                   PubMed
               73.      Barbanti M, Costa G, Picci A, et al. Coronary cannulation after transcatheter aortic valve replacement: the RE-ACCESS study. JACC
                   Cardiovasc Interv 2020;13:2542-55.  DOI  PubMed
               74.      Bleiziffer S, Simonato M, Webb JG, et al. Long-term outcomes after transcatheter aortic valve implantation in failed bioprosthetic
                   valves. Eur Heart J 2020;41:2731-42.  DOI  PubMed
               75.      Chakravarty T, Søndergaard L, Friedman J, et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic
                   valves: an observational study. Lancet 2017;389:2383-92.  DOI  PubMed
               76.      Blanke P, Leipsic JA, Popma JJ, et al; Evolut Low Risk LTI Substudy Investigators. Bioprosthetic aortic valve leaflet thickening in the
                   evolut low risk sub-study. J Am Coll Cardiol 2020;75:2430-42.  DOI  PubMed
               77.      De Backer O, Dangas GD, Jilaihawi H, et al; GALILEO-4D Investigators. Reduced leaflet motion after transcatheter aortic-valve
                   replacement. N Engl J Med 2020;382:130-9.  DOI  PubMed
               78.      Makkar RR, Fontana G, Jilaihawi H, et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med
                   2015;373:2015-24.  DOI  PubMed
               79.      Dangas GD, Tijssen JGP, Wöhrle J, et al; GALILEO Investigators. A controlled trial of rivaroxaban after transcatheter aortic-valve
                   replacement. N Engl J Med 2020;382:120-9.  DOI  PubMed
               80.      Nijenhuis VJ, Brouwer J, Delewi R, et al. Anticoagulation with or without Clopidogrel after transcatheter aortic-valve implantation. N
                   Engl J Med 2020;382:1696-707.  DOI  PubMed
               81.      Brouwer J, Nijenhuis VJ, Delewi R, et al. Aspirin with or without Clopidogrel after transcatheter aortic-valve implantation. N Engl J
                   Med 2020;383:1447-57.  DOI  PubMed
               82.      Makkar RR, Blanke P, Leipsic J, et al. Subclinical leaflet thrombosis in transcatheter and surgical bioprosthetic valves: PARTNER 3
                   cardiac computed tomography substudy. J Am Coll Cardiol 2020;75:3003-15.  DOI  PubMed
               83.      Abdel-Wahab M, Simonato M, Latib A, et al. Clinical valve thrombosis after transcatheter aortic valve-in-valve implantation. Circ
                   Cardiovasc Interv 2018;11:e006730.  DOI  PubMed
               84.      Ten Berg J, Sibbing D, Rocca B, et al. Management of antithrombotic therapy in patients undergoing transcatheter aortic valve
                   implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous
                   Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease. Eur Heart J 2021;42:2265-9.
                   DOI  PubMed
               85.      Jose J, Sulimov DS, El-Mawardy M, et al. Clinical bioprosthetic heart valve thrombosis after transcatheter aortic valve replacement:
                   incidence, characteristics, and treatment outcomes. JACC Cardiovasc Interv 2017;10:686-97.  DOI  PubMed
               86.      Vahidkhah K, Javani S, Abbasi M, et al. Blood stasis on transcatheter valve leaflets and implications for valve-in-valve leaflet
                   thrombosis. Ann Thorac Surg 2017;104:751-9.  DOI  PubMed
               87.      Brown ML, Park SJ, Sundt TM, Schaff HV. Early thrombosis risk in patients with biologic valves in the aortic position. J Thorac
                   Cardiovasc Surg 2012;144:108-11.  DOI  PubMed
               88.      Eggebrecht H, Schmermund A, Voigtländer T, Kahlert P, Erbel R, Mehta RH. Risk of stroke after transcatheter aortic valve
                   implantation (TAVI): a meta-analysis of 10,037 published patients. EuroIntervention 2012;8:129-38.  DOI  PubMed
               89.      Eitan A, Brinkmann C, Haselbach T, Witt J, Schofer J. Does valve in valve TAVR carry a higher risk for thromboembolic events
                   compared to native valve TAVR? Catheter Cardiovasc Interv 2020;95:1017-21.  DOI  PubMed
               90.      Macherey S, Meertens M, Mauri V, et al. Meta-analysis of stroke and mortality rates in patients undergoing valve-in-valve
                   transcatheter aortic valve replacement. J Am Heart Assoc 2021;10:e019512.  DOI  PubMed  PMC
   81   82   83   84   85   86   87   88   89   90   91